# T&L Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-l-biotechnology

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.seafrom.com
- Total disclosed funding: $15M
- Latest round: Series A (Mar 20, 2023)
- Investors on record: 2

## About

Based in Beijing, China, and founded in 2011, T&L Biotechnology operates as a cell and gene therapy services provider that provides products and services for life sciences. It has established a 2000? R&D laboratory and clean workshop. It reached a strategic partnership with Youjia Biological to promote nucleic acid drug development. The company engages in provides raw material reagents and services for cell and gene therapy drugs, antibody drug development, cell storage, and other biopharmaceutical and IVD fields. The products can be categorized into humanized antibodies, cytokines, immune magnetic beads, DNA/RNAi reagents, target proteins, and culture media. It also provides technical services including recombinant protein expression development, pilot production and process optimization, cell commissioning service, antibody production, and preparation development. In June 2025, T&L Biotechnology raised amount of strategic investment from new investor Beibu Gulf Private Equity Management.

## Funding rounds

- Series A, Mar 20, 2023, $15M — Fortune Capital, Harvest Capital

## Investors

- Fortune Capital — Series A
- Harvest Capital — Series A